Podcasts about Laurie Garrett

What dangers does an RFK Jr HHS pose to Americans, really? Derek dives into science writer's Laurie Garrett's work, who spoke to the dangers we're facing today in 1994—and who has raised an alarm about the consequences of destroying public health ever since. Show Notes The Coming Plague — Laurie Garrett Betrayal of Trust — Laurie Garrett Laurie Garrett on This Week in Virology Learn more about your ad choices. Visit megaphone.fm/adchoices

Health and science are under siege. The attack on long-held principals of science and our healthcare system certainly aren't new, but they have reached a fevered pitch under this administration. Pulitzer Prize-winning journalist Laurie Garrett and Dr. Kavita Patel join David Rothkopf to diagnose the problems and examine the severe consequences of this moment.  Learn more about your ad choices. Visit megaphone.fm/adchoices

Health and science are under siege. The attack on long-held principals of science and our healthcare system certainly isn't new, but they have reached a fevered pitch under this administration. Pulitzer Prize-winning journalist Laurie Garrett and Dr. Kavita Patel join David Rothkopf to diagnose the problems and examine the severe consequences of this moment.  Learn more about your ad choices. Visit megaphone.fm/adchoices

The Rev. Dr. Laurie Garrett-Cobbina Dean of the San Francisco Theological Seminary, Shaw Chair for CPE Program, and Professor of Pastoral Care and Education at San Francisco Theological Seminary/University of Redlands, San Anselmo, CA. The Rev. Dr. Martin Luther King legacy we gather to celebrate today matters. Just as Jesus revealed the power and glory of God through how he acted, what he said, who he befriended, who he included, Martin Luther King's prophetic ministry reveals something powerful to society, the religious world in general, and the Christian Church in particular. Our gathering today is God, again, breaking into our self-interests and telling us to hear the sound of freedom, and see today as an original moment to strive for justice and freedom, not just as a figment of fond remembrance.

The Breakdown is LIVE at 9pm ET with Laurie Garrett and Zack Czajkowski

The Breakdown is live w/ guests Dr. Vin Gupta and Laurie GarrettThis week on The Breakdown hosts Tara Setmayer and Rick Wilson discuss the state of the pandemic, vaccine development, and President Biden's COVID-19 rescue package with Pulmonologist Dr. Vin Gupta and Pulitzer Prize-winning public health journalist Laurie Garrett. Don't miss a moment – watch now, share on social media, and follow The Lincoln Project below. Join the fight at LincolnProject.us! FOLLOW Dr. Vin GuptaTWITTER: @VinGuptaMD Follow Laurie Garrett TWITTER: @Laurie_Garrett FOLLOW LINCOLN PROJECTTWITTER: https://bit.ly/3zwZFva INSTAGRAM: https://bit.ly/31yyrHR FACEBOOK: https://bit.ly/3zCBHhT PODCAST: https://apple.co/3G7zr4L

Original Air Date: October 11, 2023 This week's installment of the Road to COP 28 features the second half of a discussion from a panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Tune in for the rest of their conversation on what actions both individuals and governments must take to combat climate change. In addition, we've included a segment from our recent conversation with Dr. Michael Mann, who shares his outlook for the COP 28 conference. Learn more about your ad choices. Visit megaphone.fm/adchoices

Original Air Date: October 11, 2023 This week's installment of the Road to COP 28 features the second half of a discussion from a panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Tune in for the rest of their conversation on what actions both individuals and governments must take to combat climate change. In addition, we've included a segment from our recent conversation with Dr. Michael Mann, who shares his outlook for the COP 28 conference. Learn more about your ad choices. Visit megaphone.fm/adchoices

Original Air Date: October 3, 2023 The third episode in our Road to COP 28 series is here. This week's episode focuses on Green Growth and is chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Don't miss their critical conversation on what needs to be done to get us to a more sustainable future and the numerous challenges ahead of COP 28. Learn more about your ad choices. Visit megaphone.fm/adchoices

Original Air Date: October 3, 2023 The third episode in our Road to COP 28 series is here. This week's episode focuses on Green Growth and is chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Don't miss their critical conversation on what needs to be done to get us to a more sustainable future and the numerous challenges ahead of COP 28. Learn more about your ad choices. Visit megaphone.fm/adchoices

With Norm away this week, Kavita is joined by Laurie Garrett for a conversation on a potpourri of topics. From the situation in Israel, to the House speaker race, to updates on COVID, there is a little bit of everything in this week's episode. Don't miss it! Learn more about your ad choices. Visit megaphone.fm/adchoices

With Norm away this week, Kavita is joined by Laurie Garrett for a conversation on a potpourri of topics. From the situation in Israel, to the House speaker race, to updates on COVID, there is a little bit of everything in this week's episode. Don't miss it! Learn more about your ad choices. Visit megaphone.fm/adchoices

With Norm away this week, Kavita is joined by Laurie Garrett for a conversation on a potpourri of topics. From the situation in Israel, to the House speaker race, to updates on COVID, there is a little bit of everything in this week's episode. Don't miss it! Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's installment of the Road to COP 28 features the second half of a discussion from a panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Tune in for the rest of their conversation on what actions both individuals and governments must take to combat climate change. In addition, we've included a segment from our recent conversation with Dr. Michael Mann, who shares his outlook for the COP 28 conference. This material is distributed by TRG Advisory Services, LLC on behalf of the Embassy of the United Arab Emirates in the U.S.. Additional information is available at the Department of Justice, Washington, DC. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's installment of the Road to COP 28 features the second half of a discussion from a panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Tune in for the rest of their conversation on what actions both individuals and governments must take to combat climate change. In addition, we've included a segment from our recent conversation with Dr. Michael Mann, who shares his outlook for the COP 28 conference. This material is distributed by TRG Advisory Services, LLC on behalf of the Embassy of the United Arab Emirates in the U.S.. Additional information is available at the Department of Justice, Washington, DC. Learn more about your ad choices. Visit megaphone.fm/adchoices

This week's installment of the Road to COP 28 features the second half of a discussion from a panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Tune in for the rest of their conversation on what actions both individuals and governments must take to combat climate change. In addition, we've included a segment from our recent conversation with Dr. Michael Mann, who shares his outlook for the COP 28 conference. This material is distributed by TRG Advisory Services, LLC on behalf of the Embassy of the United Arab Emirates in the U.S.. Additional information is available at the Department of Justice, Washington, DC.

The first episode from our Green Growth panel in the Road to COP 28 series is here. This week's episode features a new panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Don't miss their critical conversation on what needs to be done to get us to a more sustainable future, and the numerous challenges ahead of COP 28. Learn more about your ad choices. Visit megaphone.fm/adchoices

The first episode from our Green Growth panel in the Road to COP 28 series is here. This week's episode features a new panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Don't miss their critical conversation on what needs to be done to get us to a more sustainable future, and the numerous challenges ahead of COP 28. Learn more about your ad choices. Visit megaphone.fm/adchoices

The first episode from our Green Growth panel in the Road to COP 28 series is here. This week's episode features a new panel of experts chaired by Frederick “Fritz” Mayer, Dean of the Josef Korbel School of International Studies. Our panel of experts includes author and science journalist Laurie Garrett, NASA Climate Scientist Peter Kalmus, Professor at the University College London Mark Maslin, Professor at Yale School of the Environment Robert O. Mendelsohn, Associate Professor in the Rutgers School of Environmental and Biological Sciences Karen M. O'Neill, Associate Professor at the University of California Santa Cruz and the Rutgers School of Environmental and Biological Sciences Malin L. Pinsky, and Director of USC Annenberg's Center for Climate Journalism and Communication Allison Agsten. Don't miss their critical conversation on what needs to be done to get us to a more sustainable future, and the numerous challenges ahead of COP 28. This material is distributed by TRG Advisory Services, LLC on behalf of the Embassy of the United Arab Emirates in the U.S.. Additional information is available at the Department of Justice, Washington, DC.

This podcast is a commentary and does not contain any copyrighted material of the reference source. We strongly recommend accessing/buying the reference source at the same time. ■Reference Source https://www.ted.com/talks/laurie_garrett_lessons_from_the_1918_flu ■Post on this topic (You can get FREE learning materials!) https://englist.me/298-academic-words-reference-from-laurie-garrett-lessons-from-the-1918-flu-ted-talk/ ■Youtube Video https://youtu.be/2jut8UwdUWM (All Words) https://youtu.be/Ghy4LQxfEn4 (Advanced Words) https://youtu.be/eY79CwsUuZI (Quick Look) ■Top Page for Further Materials https://englist.me/ ■SNS (Please follow!)

In this summer of harrowing wildfires, temperature records the UN Secretary General calls "global boiling," and shrinking ice caps, there is a growing sense of urgency regarding the climate crisis. A major global summit will take place on the subject later this year. Climate experts Rachel Kyte, David Sandalow and science journalist Laurie Garrett discuss what the agenda must include. Plus a special update on resurgent COVID. Don't miss it. Learn more about your ad choices. Visit megaphone.fm/adchoices

In this summer of harrowing wildfires, temperature records the UN Secretary General calls "global boiling," and shrinking ice caps, there is a growing sense of urgency regarding the climate crisis. A major global summit will take place on the subject later this year. Climate experts Rachel Kyte, David Sandalow and science journalist Laurie Garrett discuss what the agenda must include. Plus a special update on resurgent COVID. Don't miss it. Learn more about your ad choices. Visit megaphone.fm/adchoices

Originally Aired: July 23, 2021 The science shows that GOP-led resistance to the vaccine is fueling a resurgence of COVID in the US. Anger against the unvaccinated is understandably growing as their ignorance and politics are putting the country at risk again. Where will this lead? What will this new wave of COVID look and feel like? What should we do about it? How does our international response figure in? We discuss these essential and urgent issues with Pulitzer Prize winning journalist Laurie Garrett, former Obama health care advisor Dr. Kavita Patel and Ryan Goodman of "Just Security." Don't miss this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

Originally Aired: July 23, 2021 The science shows that GOP-led resistance to the vaccine is fueling a resurgence of COVID in the US. Anger against the unvaccinated is understandably growing as their ignorance and politics are putting the country at risk again. Where will this lead? What will this new wave of COVID look and feel like? What should we do about it? How does our international response figure in? We discuss these essential and urgent issues with Pulitzer Prize winning journalist Laurie Garrett, former Obama health care advisor Dr. Kavita Patel and Ryan Goodman of "Just Security." Don't miss this episode. Learn more about your ad choices. Visit megaphone.fm/adchoices

Where we are nowSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Originally Aired: January 14, 2021 It has been two years since COVID-19 started hitting the headlines globally. As the new omicron variant is causing surging caseloads across America and around the world, it seems as though the end of this moment is very far away. What mistakes have we made? What should the Biden administration be doing next? How does the pandemic connect to the fight to protect democracy? What does the Supreme Court decision on the vaccine mandate mean for the fight against the virus? To answer these and other pressing questions, DSR Host David Rothkopf spoke with Kavita Patel of the Brookings Institution and Pulitzer Prize winning journalist Laurie Garrett. Don't miss this timely conversation. Learn more about your ad choices. Visit megaphone.fm/adchoices

Originally Aired: January 14, 2021 It has been two years since COVID-19 started hitting the headlines globally. As the new omicron variant is causing surging caseloads across America and around the world, it seems as though the end of this moment is very far away. What mistakes have we made? What should the Biden administration be doing next? How does the pandemic connect to the fight to protect democracy? What does the Supreme Court decision on the vaccine mandate mean for the fight against the virus? To answer these and other pressing questions, DSR Host David Rothkopf spoke with Kavita Patel of the Brookings Institution and Pulitzer Prize winning journalist Laurie Garrett. Don't miss this timely conversation. Learn more about your ad choices. Visit megaphone.fm/adchoices

XBB.1.5 is being called the most transmissible subvariant of Omicron to date. With multiple mechanisms to evade our immune system, including getting around our monoclonal antibody treatments, it's driving our January wave and leading to worse outcomes than previous mutations. Andy speaks with science journalist Laurie Garrett, who explains what makes XBB.1.5 unique and why the lack of global surveillance and federal funding could easily erode the advances we've made so far to combat COVID. Keep up with Andy on Twitter and Post @ASlavitt. Follow Laurie Garrett on Twitter @Laurie_Garrett. Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.    Support the show by checking out our sponsors! Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: https://lemonadamedia.com/sponsors/    Check out these resources from today's episode:  Find vaccines, masks, testing, treatments, and other resources in your community: https://www.covid.gov/ Order Andy's book, “Preventable: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response”: https://us.macmillan.com/books/9781250770165  Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.  For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble.See omnystudio.com/listener for privacy information.

Welcome back to the fifth year of Gaslit Nation and the fiftieth year of the quest for Donald Trump's tax returns!  This week we discuss a panoply of government criminals and their dirty donors, ranging from newly minted oligarch cash receptacle “George Santos” (or whatever his name really is) to fellow recipients of mafia money in Congress (sadly it's nearly everyone) to Trump's half-century free ride from the IRS (because, again, they're all in on it!) to the backers of Putin and Netanyahu's wars (again it's the same network enabling the crimes!) We also discuss the chaos and corruption that will ensue under a GOP House, the disturbing rhetoric of new Democratic House Minority Speaker Hakeem Jeffries, and give an update into Putin's war on Ukraine. We come fully armed with receipts and discuss what this entrenched corruption means for American democracy in the year 2023, a year in which Congress may have lost its illusions but has not found its soul. We discuss the lackluster release of Trump's tax returns and stress the urgent need for release of his returns going back to the 1970s, which is when he allegedly made a pact with the US government to not pay taxes for thirty years in return for unnamed favors. (Read about it in Sarah's book HIDING IN PLAIN SIGHT which is having a $2.99 Kindle sale.) We are recording our weekly bonus episode, available to Patreon subscribers at the Truth-Teller level or higher, on Wednesday to mark the second anniversary of the January 6 attack on the Capitol and the continued inaction of Merrick Garland's DOJ to hold the organizers accountable. We will also be answering your questions so please keep them coming! If you subscribe to Gaslit Nation at the Democracy Defender level or higher, you can ask us anything you want and we will answer it in depth! Subscribers at that level are also invited to a live Gaslit Nation taping on January 24! Stay tuned for more details and thank you for your continued support of the show – we could not make it without you. Show Notes: Russian Oligarch's Cousin Funneled Cash to N.Y. Politician https://www.thedailybeast.com/republican-george-devolder-santos-got-cash-from-andrew-intrater-cousin-of-russian-oligarch-viktor-vekselberg Conservatives turn to a new message: ‘God bless the Ukrainian people' https://www.washingtonpost.com/politics/2022/02/27/conservatives-cpac-ukraine/ Here's the first evidence Russia used Twitter to influence Brexit https://www.wired.co.uk/article/brexit-russia-influence-twitter-bots-internet-research-agency Scrutiny mounts over tech investments from Kremlin-connected expatriates https://www.washingtonpost.com/technology/2022/12/19/russia-expatriates-links-probed/ The Russia Investigations: Another Oligarch Becomes Embroiled In The Imbroglio https://www.npr.org/2018/05/12/610466404/the-russia-investigations-did-a-nice-oligarch-pay-trump-s-lawyer Russian Oligarch's Cousin Funneled Cash to N.Y. Politician https://www.thedailybeast.com/republican-george-devolder-santos-got-cash-from-andrew-intrater-cousin-of-russian-oligarch-viktor-vekselberg Moscow Heat: George Santos and His Moscow Trips https://petestrzok.substack.com/p/moscow-heat?r=1pz15w&utm_campaign=post&utm_medium=web Russians getting seized off the street by police to go fight in Ukraine https://twitter.com/Laurie_Garrett/status/1609668327525203969 Firm Tied to Russian Oligarch Made Payments to Michael Cohen https://www.nytimes.com/2018/05/08/us/politics/michael-cohen-shell-company-payments.html A tiny paper broke the George Santos scandal but no one paid attention https://www.washingtonpost.com/media/2022/12/29/north-shore-leader-santos-scoop/ GOP operative convicted in scheme to funnel Russian money into Trump campaign https://www.axios.com/2022/11/18/trump-campaign-jesse-benton-russia $858,000,000,000 - by Judd Legum - Popular Information SBF and the Injustice Democrats - by Max Berger (substack.com) Republican George Devolder-Santos Got Cash From Andrew Intrater Cousin of Russian Oligarch Viktor Vekselberg (thedailybeast.com) The Ties That Bind: Ehud Barak's Business Network - CTech (calcalistech.com) ‘Israel today, Israel tomorrow, Israel forever,' Rep. Hakeem Jeffries says at NY rally – Mondoweiss  

Laurie Garrett discusses the role of wastewater testing in public health and her idea of a device that could be used by anyone to analyze water samples. This podcast is not an episode of TWiV, but I thought it would be of interest to listeners. Laurie Garrett and Vincent Racaniello Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email Become a patron of TWiV! Links for this episode Support MicrobeTV with a Spike t-shirt (Vaccinated.us) Coliform testing of water in Florida (YouTube) Declining cost of genome sequencing (Illumina) National wastewater surveillance system (CDC) Advances in detection of viruses in wastewater (Med Express) Wastewater monitoring comes of age (Nature) Monitoring monkeypox virus in wastewater (Med Express) Poliovirus wastewater surveillance in NY (Dept of Health) Wastewater surveillance in NYS (Dept of Health) Estimating norovirus infections through wastewater (Water Res) Estimating antimicrobial resistant bacteria through latrine water (Antimicro Res Inf Control) Intro music is by Ronald Jenkees Send your questions and comments to twiv@microbe.tv

Demetre Daskalakis, deputy coordinator of the White House national monkeypox response, and Jeremy Youde, dean of the College of Arts, Humanities, and Social Sciences at the University of Minnesota Duluth, discuss the emergence of monkeypox and other diseases, international responses, and messaging around health issues that especially affect the LGBTQ+ community. Jennifer Nuzzo, senior fellow for global health at CFR, moderates. Learn more about CFR's Religion and Foreign Policy Program. FASKIANOS: Thank you, and welcome to the Council on Foreign Relations Social Justice Webinar series. The purpose of this series is to explore social justice issues and how they shape policy at home and abroad through discourse with members of the faith community. I'm Irina Faskianos, vice president of the National Program and Outreach here at CFR. As a reminder, this webinar is on the record, and it will be made available on CFR's website, CFR.org, and on the iTunes podcast channel, “Religion and Foreign Policy.” As always, CFR takes no institutional positions on matters of policy. We're delighted to have Jennifer Nuzzo, senior fellow for global health at CFR, to moderate today's discussion on infectious diseases. Dr. Nuzzo is a senior fellow for global health here at CFR. She's also a professor of epidemiology and the inaugural director of the Pandemic Center at Brown University's School of Public Health. Her work focuses on global health security, public health preparedness and response, and health systems resilience. In addition to her research, she directs the Outbreak Observatory, which conducts operational research to improve outbreak preparedness and response. And she advises national governments, and for-profit and non-profit organizations on pandemic preparedness and response, and worked tirelessly during the COVID pandemic to advise and tell people what was going on, to the extent that we knew, as we made our way through this two-and-a-half-year pandemic. So, Jennifer, I'm going to turn it over to you to introduce our speakers. NUZZO: Great. Thank you, Irina. Thanks for that introduction and thanks for organizing this webinar today. I'm very glad that we're having this conversation. As someone who's worked in infectious diseases for my entire career, I have found the last few years to be particularly staggering. I was looking, and as of today there are more than 616 million cases of COVID-19 that have been reported globally, upwards of 6.5 million diagnosed deaths that have been reported worldwide. At the same time, we are also seeing a global surge in cases of monkeypox, a disease that many hadn't heard of prior to this past year. And now we are over 66,000 cases that have been reported globally, more than 25,000 of those reported here in the United States alone. At the same time, successive outbreaks of Ebola have been occurring, and we have measles once again on the rise. And now vaccine-derived polio circulating in countries where the virus had been previously thought to be eliminated. So it's really a staggering list of infectious diseases that have been occurring and continue to occur. So clearly, we're at an important crossroads in terms of how we respond to these recurring hazards and infectious disease emergencies. But today we get to zoom out a little bit, and to examine factors that they may have all in common, and to try to understand what may be driving these—the recurrence of these events over and over again. So over the past few years we have seen the consequences of social, economic, and racial inequities play out center stage. These factors have underpinned not only our underlying vulnerabilities to infectious diseases, but also how effectively we respond to them. So that's what we're going to talk about today. And to help discuss these issues we are joined by two globally renowned experts who have a long history in working to address infectious disease threats and the disparities that accelerate them. Our first panelist is Dr. Demetre Daskalakis. Dr. Daskalakis is the deputy coordinator of the White House national monkeypox response. Prior to this role, he served as director of CDC's division of HIV prevention. And prior to that, oversaw infectious diseases for the New York City Department of Health and Mental Hygiene, which is one of the largest health departments in the nation and rivals the WHO in terms of staff and budgets. So Dr. Daskalakis is a leading national expert on many things, but also in particular health issues affecting the LGBTQIA+ communities. And he has worked clinically for much of his career to focus on providing care for these communities. We are also joined by Dr. Jeremy Youde, who is the dean of the College of Arts, Humanities, and Social Sciences at the University of Minnesota Duluth. Previously, Dr. Youde was an associate professor in the department of international relations at Australia National University in Canberra. Dr. Youde is an internationally recognized expert on global health politics. And he is a very prolific writer. He has written five books, and many chapters, and countless articles. I recently read a very compelling blog post by him on our own CFR's Think Global Health. So really excited to get both Dr. Youde and Dr. Daskalakis's perspectives on the issues in front of us. So I will get the conversation started. We have a lot of great attendees, and we'll have time for questions. But just to get the conversation going, let's see here. Maybe first, if I could turn to you, Dr. Demetre. For those who haven't been living in the monkeypox data as much as you have, perhaps you could just give us a quick summary of where we are and where you see us being headed. DASKALAKIS: Thank you. And thank you for having me. I'm really excited to join Jeremy and to be a part of this discussion. So living in the data is, in fact, what I do. So I'll tell you, so monkeypox—I'll give a little key bit of background just for everyone to be level-set—is an orthopoxvirus, that is a virus that causes disease, transmitted usually from animals to humans. Usually, traditionally, not a lot of human-to-human transmission. This current outbreak in 2020, global in scale, with 66,500 cases reported internationally, actually demonstrates pretty good human-to-human transmission, often in the setting of close contact, often associated with sexual activity, and the majority of cases being among men who have sex with men—the vast majority, over 96 percent. In the U.S., at this moment, we have 25,300 cases. I can tell you right up to the moment. And so we continue to see increases in cases in the United States, but we're seeing a deceleration in the rate of increase. So cases are stilling being logged. We used to see kind of around four hundred cases per day. We're now more on the order of two hundred or below and continue to see that trend going in a good direction with more data imminently coming to the website of CDC later on today. Again, just briefly, the demographic, majority male, mainly men who have sex with men—the gay, bisexual, other men who have sex with men. Looking at the demographics, at the beginning of the outbreak in May, the majority of cases were among white men. And now we're seeing about 68 percent of those cases are happening in Latino or Black men. From the perspective of that measure as well we've seen a significant increase in vaccinations. So we can talk—we're going to talk more about that, I'm sure. But really with lots of strategies to increase vaccine supply. We are now well over eight hundred thousand vaccines administered. There is an inequity there as well. The majority of vaccines are going to white men. And we're seeing Latino men and Black men in second and third place, respectively, in terms of vaccines administered. Jennifer, I hope that that's a good situation summary to start off with. NUZZO: Yeah, great summary. Thank you so much. That helped kind of bring everybody to the same—somewhat same level. Just a quick follow-up question for you. There have been a lot of headlines about the important progress we've made, and the fact that the global monkey—or, sorry—the monkeypox cases seem to be coming down in terms of numbers. Question: Are you seeing similar trends for all demographics? Or are you concerned that perhaps the large numbers are hiding increased transmission in other groups? DASKALAKIS: I had to fix the mute. There we go. So I think what we've seen is that the declines are looking to be even across population. So that's good news. Again, the vaccine equity is our main issue right now in terms of where we're—where that's stubborn right now, and really thinking about strategies to improve that. We had a lot of news today, which I'm sure we'll be able to talk about some of the strategies that we have to address that. But so I think there's no clear sign that the deceleration is different in different populations. Geographically, however, it is different. And so that's, I think, one place where—the jurisdictions that have had the greatest and longest experience with this outbreak, so the most cases, are also the jurisdictions that have access to the most vaccines. So whether it's because of behavior change that we're seeing, which is definitely something that we, I imagine, could talk about here as well, or natural infections plus vaccine-induced immunity, I think the places that have had more experience are showing deceleration faster. So New York, California, Texas, and Georgia are looking down, while some of the places where the outbreak is newer and they've also had less access and time for vaccines, those places are showing an increase. We're going to get an update of this, this week. So this is based on data that's about a month old. So soon we're going to have a new view into how this deceleration or acceleration looks like, jurisdiction by jurisdiction. NUZZO: Great. Thank you. Maybe turn to you, Dr. Youde. You've been an important voice about the global dimensions of the monkeypox crisis. And I'm just curious where you think we are globally. And I referenced in introducing you that piece that you wrote on Think Global Health that I thought was—made a quite compelling argument about the role of WHO and where you see the response needing to go. Do you want to maybe elaborate on those points for people who haven't had a chance to read your article? YOUDE: Sure. Thank you for the question, and thanks for organizing this. I'm honored to be part of this event. And, picking up on some of what you were talking about and what Demetre was just talking about as well, we do see these inequities that exist, especially when we're looking worldwide. The World Health Organization did declare monkeypox a public health emergency of international concern. And while it doesn't necessarily come with automatic funding or programmatic resources, it does raise the profile. It does put this on the global health agenda and say: This is something we need to be paying attention to. In the piece I described it as the WHO's bat signal. We're sending out the message: This is something that we need to pay attention to. But one of the things I think is frustrating about the WHO response, and just sort of the global community's response to monkeypox in general, is that monkeypox isn't a new disease. This is a disease that we've known about in human cases since 1970. Laurie Garrett in her book, The Coming Plague, which came out in '94—which is one of the books I think a lot of us who are probably about a similar age read in our early, formative days as we were coming into global health and global health politics—she talks about it in that book. And if you look at the data that we have, we've been seeing increases in monkeypox cases in humans in countries where monkeypox was endemic for about the last decade or so. And so—but what really caught the international community's attention was then when it came to the Global North, when it came to the industrialized countries. And that helps to reinforce some of these questions about what is the nature of our real concern about global health? Is it about health in this very broad mandate, like the World Health Organization has as part of its constitutional mandate, to be this international coordinating body? Or is the sense that we, in the Global North, want to keep the diseases from the Global South coming to affect us? And there are similar sorts of issues when we're looking at vaccine equity and vaccine access, when we're looking globally. And, there have certainly been some problems here in the United States, getting access to the vaccine. But, I was able to get vaccinated against monkeypox. Yeah, I had to drive two and a half hours to Minneapolis to do it, but I was able to do it. And I was able to arrange it. People in countries where monkeypox is endemic have little to no access to these vaccines. And it raises some of the questions then, again, about how the international system and the global health governance systems that we have in place—how they can address some of these equity challenges? Because in many ways, outbreaks like monkeypox, they glom onto the societal and social cleavages that exist, and help to reinforce and exacerbate them, but also provide this opportunity for us to really put some of our ideals and our promises around social justice, around a cosmopolitan view of understanding that we are all healthier if we are all healthier. And really put those into practice, if we have the political and economic will to do so. And that's where—that's one of the areas where I get a bit concerned right now. I know we're all exhausted talking about COVID-19 and about monkeypox, and all of these sorts of outbreaks. Jennifer, I know you've been doing a lot of this. Demetre, obviously, you've been on the frontlines. I've been doing some of this work as well. But when we lose that attention, sometimes we lose then that motive—that momentum in the political system to try to address some of these challenges and these shortfalls that we have identified. So, I can be a critic of the World Health Organization, but I also recognize that the World Health Organization is a creature of its member states. And so, it's really incumbent upon the member states to really put some action behind their words. And to say: If we want to have a more effective response, we need to build systems that are going to be able to respond better than this. NUZZO: Thank you for that. It's a good segue to what I wanted to talk about next, which is the title of this webinar being about social justice. And those who've worked in public health, the notion that social justice has a role to play in reducing our vulnerability to infectious disease is quite clear. But I'm aware, particularly over watching—(laughs)—the national political debate over the last several years that those outside of public health may not recognize the connection between our vulnerability to infectious diseases and social justice. And they may be dismissive of the idea that public health authorities should be engaged in the work of social justice. So this is actually a question for you both. And maybe reflect on monkeypox or your long experience of other infectious disease threats that you've worked to address. And what would you say to folks that just don't understand why public health should be concerned with social justice, and what role do you think it has to play going forward? And maybe we'll turn back to you after Demetre. DASKALAKIS: Do you want Jeremy to go or do you want me to go first? NUZZO: Go ahead. YOUDE: Go for it. Go for it. I'll let you start. DASKALAKIS: All right. So I'll put my very strong HIV hat on, because that's sort of where I come from. And I'll start that this is a forty-one—a forty-two, almost, year-old lesson that I think we've seen play out over and over again, which is that really the social determinants of health are actually what drive infection. So there are countermeasures that can work. There's vaccines. There's drugs. There's pre-exposure prophylactics, post-exposure prophylactics. It doesn't matter. The social determinants are really what ultimately ends up blocking us from being able to implement the full vision of what we know we can from the perspective of medical technology and public health. And so I think that at the end of the day that implementation piece is so critical. So much technology can exist, so many interventions can be designed, but they sit on the shelf unless there's both the political and social will to move them forward. And so I think I should put that HIV hat there for a second, because in environments where there is less political and social will we tend to see HIV flourish. And in places where there is social and political will, we tend to see HIV not do so well from the perspective—or, in other words, we will do well because of less incidents and prevalence. So I think that sort of looking at that will is so critical. I'll give you a story from monkeypox which I think is really important, that is about the sort of CDC response. I got pulled in really early on, before the first case actually hit the United States. One of the very early conversations that we had with the response is that we need to expect that we're going to have inequities that are going to be a part of this. And I think that's based on lessons from COVID, and lessons from HIV, and lessons from so many other infections. I think we really worked to make equity the cornerstone of the response. But even when you do that, it is an all-of-society thing that needs to happen, and not just something that is mediated simply by a public health department or a public health agency. Over. YOUDE: And if I can take that public health hat and HIV hat that you had on, and I'll wear it myself. I got into this line of work through working on HIV/AIDS issues in Zimbabwe and South Africa, and seeing how those sorts of societal cleavages played a role, but then also how infectious disease outbreaks, and the spread of HIV was glomming into these other issues around democratization, around building societies that were going to be equitable, that were going to be able to fulfill the promises that governments had made to their populations. And seeing how a disease like this was thwarting that progress. So it's something that is not just unique to the United States. It's something that we see globally. From a very instrumental perspective we can say, look, public health is ultimately a weakest link public good. Everyone is still at risk, so long as risks still exist. So we need to reach out to those places which might have fewer resources, which might not have the same sorts of ability to implement these sorts of programs, because ultimately that's going to make us all healthier. And I think there's elements and an important role for those sorts of instrumental views of public health. But I also think about the recently passed Paul Farmer, and his notion of public health, especially his idea around the preferential option for the poor, which was kind of a double-edge sword. Because on the one hand he was saying, look, the people who are disenfranchised within societies, those are the people who are the most vulnerable to these infectious disease outbreaks. Those are the people who are at the greatest risk. But also, we need to think about our programs, we need to think about our interventions putting those people first, thinking about equity. Putting that not as an afterthought or something that we think about five, six, seven steps down the road, but it needs to be central, and it needs to be core. Because, again, if we're not taking equity seriously and we're not really putting this into everything that we're doing, then we're just reinforcing these sorts of divisions and, again, providing these opportunities and these outlets where diseases can thrive. And so, to just cosign what Demetre was saying we can have all the technologies we want. And I have all my criticisms about the way that the access to pharmaceuticals and drug interventions exist on a global level, and questions about compulsory licensing and all these sorts of things. Those are all important, but those are secondary in a lot of respects if we don't have the underlying core infrastructure in place. And that core infrastructure, even if it's not touching us in a direct way, does have an effect on our ability to stay healthy. DASKALAKIS: Could I—this is a fun one. Could I keep going a little bit longer on this? NUZZO: Please do, yeah. DASKALAKIS: This is a great, stimulative conversation on this. And along with what ends up being both the foundation of the issue as well as the deeper foundation, the way that all of these social issues interact with stigma, like I think we've seen in fast-forward with monkeypox. Like all the things that we saw with HIV and other infections and COVID—today, for instance—this is a really good example. So, we're giving the vaccines and right now they're going on people's forearms. Which means that literally some people will have a mark on their forearm. So talking about stigma—literally stigma. And so, we changed it so that individuals can elect to get the vaccine on their shoulder or on their back. So we have people who want vaccines but are saying, I don't want to be marked by this. I don't want to have the sort of—someone know that I am someone who's potentially identifying myself as part of a group at risk. And so it interacts exactly with the social determinants. Whether it's poverty, transportation, racism, all of it interacts in a way where these sort of more brass-tacks economic issues interact with these very profound stigma issues and create barriers where even if you do have great access—I'll give an example again. [The] Ryan White [program] is really great access for people for HIV medication, but we still don't have everybody in the country—(inaudible)—right? So why is that? It's partially access, but it's also that the systems are built to sort of maintain structures of stigma and structures of inequity that are really hard to overcome, even with things that provide access. NUZZO: So I was actually going to ask you about stigma. So thank you for segueing to it. And I seems to me that—and I don't have the HIV hat to wear, like you both do. But studying events that we typically think about in the field of health security—which is a field that sort of struggles to incorporate the forty-plus year lessons that HIV has learned—is that it is clear that stigma is an issue in nearly every single event. Any time we have particularly a new infectious disease, or something that's unusual, society seems to look for some group to blame. But what it seems, though, is that while there's an increasing recognition of the importance of stigma, it doesn't seem like we have great strategies for addressing it. And I guess I'm wondering, do you agree? And also, what practically can and should we be doing to address stigma? I really saw us struggle with this. I mean, we had a recognition of it as being important in monkeypox, but I feel that the absence of clear ways to deal with it really led us to struggle to talk about monkeypox, and who was at risk, and how people could protect themselves. So what should we be doing going forward not just for monkeypox but future threats, so that we don't get hobbled by—first of all, that we can minimize or tackle stigma, but also don't get hobbled by it? Whoever wants to chime in. (Laughs.) DASKALAKIS: So this is back to the HIV hat. This is the tightrope that we walk every day in HIV. And I think that the lesson actually—well, one of the first lessons that's important, sort of sitting on the government side of the world, is that government needs to lead, and governmental public health needs to lead, so that its messaging does not propagate stigma. That's very important. Because whether people like governmental public health or not, or have complaints about it, ultimately people do look to governmental public health—like CDC, local health departments—to really fine-tune their own messaging, and then translate that messaging not just to another language but translate it so the populations that people work with actually understand. And so I think monkeypox was actually a kind of exciting example, where from the very beginning of the response it was a how can we take an anti-stigma stance in how we messaged it? And so the balance really then depended on the data. And so that's what was really important. So it was starting with imperfect data, and as the data became more and more clear, making sure that the messaging evolved in a way that addressed what you were actually seeing epidemiologically without necessarily—without creating a scenario where you're pinning infection, a virus, on a population. Let me give you an example since, Jennifer, you say your HIV hat isn't as strong as ours. So in the '80s, when HIV started, before it was HIV it was gay-related immunodeficiency. So that lesson was the lesson that was so important in the work that we did with monkeypox, to start off by saying: This is a virus that can affect anyone. But we're seeing this virus more in this population. As opposed to saying: This is this population's virus. And so it's leading by that example. And it's one of those things that we can raise up and say: We have learned the lesson from this forty-two years ago, and we're not doing it this way again. And so with that said, I think that there's a lot of strategies that can address stigma. And a lot of that has to do with communications, using trusted messengers. So, that has been a really important part of this as well because, again, working in public health I would love if everybody listened to public health data. So providing good communications to individuals who are trusted messengers is really important. And also, part of the propagating stigma is also being clear about what data is, things that we fully know and things that we're still learning. Because that really allows that risk communication so that you don't over-select or too rapidly move a response into what population, as opposed to being broad. So as you learn more data—so, for us, our guidance started off in one place about safer sex and safer gathering. As we were seeing that this was not moving throughout the different populations, it got stronger and stronger. And we really started the conversation by saying that this is guidance that's going to change as we learn more. I think that we do have stigma mitigation strategies. But stigma's a stubborn thing. I'll give it over to Jeremy. YOUDE: Yeah, I would agree with everything that you said. And especially being—having that level of humility. We are still learning about this. Things are going to change. Things are going to evolve but building those sorts of trusting relationships. The other things that I would emphasize, and I think these complement what you were saying quite well, is empowering communities to speak to each other. I think one of the things that we've seen here in the U.S. around access to the monkeypox vaccine, and the relatively high rates of vaccination that we've seen, has been people talking to other people. Men who have sex with men talking to other men who have sex with men, and this becoming part of the conversation. Even if it is something at the level of, where were you able to get access to it? When supplies are limited. Just building that sort of awareness within a community can be incredibly important. I think it's also important to make sure that we do have targeted messages. Not blaming messages, but understand that the message that just says, everyone is at risk for HIV or everyone is at risk for monkeypox, ends up falling flat and doesn't really strike anyone. And so having that sort of targeted outreach plays an important role. But going back to this point about empowering the affected communities, one of the most powerful things that I think that I've seen in the work that I've done is looking at the Treatment Action Campaign in South Africa, and the work that they did, especially in the late '90s and early 2000s, with the T-shirts that just in huge, bold letters across the chest said: HIV positive. And just having people going out there, wearing those T-shirts. The image of Nelson Mandela wearing one of those Treatment Action Campaign T-shirts is just incredibly important because, again, it's helping to remove some of that stigma. It's getting people who are trusted, who are respected, coming into the conversation. OK, if he's involved in this, if he's saying this is an important issue, maybe this is something that I need to be paying attention to. But also just trying to make that sort of availability, so that people are willing to share their experiences, or talk about what's going on, or what worked, or what didn't work for them. Again, these all play really important roles. It's never going to be perfect. It's something that we do need to keep at the forefront when these sorts of outbreaks happen. And you see some of this in some of the broader conversation around even what we call diseases, the names that we use. The fact that there is a very strong move away from geographically located names for diseases, because we don't want to stigmatize those particular communities or people who happen to be coming from those areas. Even something like that can play a really important role in helping people to think, this is something that I need to take seriously if I'm in the United States, I need to take this seriously. Even though we're talking about something like monkeypox, which isn't a geographic designator but there aren't a lot of monkeys roaming around in Minnesota. But it's something that they should be taking seriously, because of these effects and these sorts of community-based responses that help to try to destigmatize things, encourage people to get access to vaccines, or treatments, or other sorts of options that are available to them, and start to have those conversations to empower communities. NUZZO: That's great. I'm going to turn over to questions. And maybe participants can start putting their hands up. But while that's happening and before I turn it over for that section of the conversation, one last question to you both. Which is, I am deeply worried that we respond to these events as these one-offs. We have an emergency, we get emergency funding, then perceptions of the emergency being over, the funding disappears, and it's gone. And we saw that happen with COVID, where the money went away and then states had to let go their pandemic hires. And guess what? They weren't there when monkeypox happened. So I guess the question is, how do we move away from sort of seeing these as just one-off emergencies, and moving towards a role where we create a durable sort of permanent system that's in place to snap into action anytime there's an event, which is happening—which we're seeing—these events are happening with an increasing frequency? YOUDE: I'll jump in first, Jennifer. It's like you're reading the paper that I've been working on throughout the event today. And that's part of my concern about WHO designating this to be a public health emergency of international concern, when we're talking about monkeypox or COVID-19 for that matter, is the emergency framework. Public health, when it's doing its job, we don't know about it. It's something that—where we're essentially trying to stop things before they reach that level of public consciousness, or stopping it really, really early in the process. And so the emergencies, they get the attention for global health but they don't necessarily get the long-lasting system. It becomes, like, OK, whew, we got through that. We can move onto the next thing, or we can just not pay attention to global health again until the next system comes up. But at a very fundamental level we have this organization. We have the World Health Organization, which has this constitutional mandate to act as this international coordinating body for health—cross-border health issues. And it has a smaller biennial budget than many large hospital systems here in the United States. So how is it going to be able to do that sort of work when it has so few resources? Plus, given the way that the WHO is funded, it only has control over about 20 percent of its budget. The rest of it is coming through these voluntary contributions, which are generally specified for specific purposes, which may or may not align with the purposes that the WHO itself would put in place. So I think that one of the things that happens there is it behooves us, it behooves the member states to actually—to put some diplomatic and political capital behind this, to actually move on this. I have no doubt that in a few years' time we will have some sort of after—some sort of response that will look at the response that WHO made to COVID-19. And it will bemoan the failures. And it will talk about all the things that need to change. And then it will gather dust on the bookshelf. And we will get similar sorts of things for monkeypox. And what we haven't had is a country or a group of countries, or some sort of person with high stature, really glom onto this and be like, yes. We need to do this. This is our potential roadmap for trying to address this in the future. I—nerding out in the global health politics world—I had this idea that someone like a Helen Clark, or an Angela Merkel, someone who knows international politics, who knows the systems, who has that sort of diplomatic experience, but also is concerned about issues around health, that could be the person who could help to inspire some of these actions, and could get the attention of world leaders in a way that civil society organizations often aren't able to do. Which is not to say anything bad about those organizations, just that there are structural problems getting the attention of world leaders, and having that sort of concentrated attention. So I think we—ultimately, we need a champion. We need a person, or a country, or a group of countries who are willing to really champion this, and go to the mat for trying to make these sorts of changes, so it isn't just emergency, after emergency, after emergency, but something that is going to be more long lasting, that is going to provide that sort of infrastructural support, and make sure that we aren't just lurching from here, there and everywhere, but actually can have some sort of coordinated response and something that is a bit more forward-thinking. But it's a challenge. NUZZO: Demetre, the bullets of your bio—(laughs)—are a list of the emergency, after emergency, after emergency. So I know you have first-hand perspectives of this. So any hope we can fix it? DASKALAKIS: Sure do. (Laughter.) So, my perspective may be very domestic, but I actually think it's not. I think when I start talking, I think it's going to seem as if there's also infrastructure that needs to be leveraged internationally that's similar. Which is, I always think about what actually worked. And so one of the things that I think we're seeing over and over again, whether it's COVID, or monkeypox, or other outbreaks, is leveraging systems that already exist, and really figuring out how to support those systems during peacetime as well as wartime, so that it stays warm for a response. And that's a very public health—it's a very sort of operational, public health example. So I'm talking HIV. I'm talking chronic infections. I'm thinking domestically, we have this excellent—I think the HIV Epidemic Initiative, it's not nationwide yet. It hasn't been resourced to do that. But, if it were, that is a really sort of important way to be able to create and maintain an infrastructure. So thinking about sort of chronic diseases like viral hepatitis, having an infrastructure that could potentially lead to curing more people with viral hepatitis creates a system that then could be used for care and other public health delivery of countermeasures. So thinking about things that—what can we do to sort of do our peacetime work, which is around chronic infections like virus hepatitis and HIV, and what can we—and STIs, which are out of control in the United States, mainly because they're under-resourced—but what can we do sort of to maintain sort of those systems, so that when we flip the switch from peacetime to wartime that we can pivot those resources to do the work? I'll give an example from the research universe—monkeypox, as an example. Right now, there are studies that are going on for monkeypox vaccines and for monkeypox therapeutics. And they're built on the networks of HIV investigators. So, HIV Vaccine Trials Network and AIDS Clinical Trials Group are currently the people that are doing those studies. And sort of research funding potentially being a bit more flexible, that pivot is possible. But what if we had similar models sort of in the operational world of public health, where you have sexual health clinics or STD clinics that are doing HIV/STD work during peacetime, but can flip into monkeypox vaccines and testing in wartime? And so it's investing in a chronic infrastructure to be able to make it translatable into an emergency response, in a nimble way, I think is really important. And of course, I back up Jeremy. That idea of political will and leadership is really important in making sure that this sort of moves forward in a way that works. But, I mean, I say this domestically, but then one can conjure PEPFAR in terms of an infrastructure that works. So that—they have been leveraged. And so what if we worked harder to make sure that they were resourced adequately during the peacetime, so that during wartime they flip and are flipped more effective? And by the way, that HIV positive T-shirt has influenced my career, Jeremy, in terms of seeing people who were willing to put on a shirt that really works against stigma. My favorite being Annie Lennox, who I met with that T-shirt on, and I was very excited, as a fan. But definitely an important thing to reclaim that stigma. Jennifer, thank you. YOUDE: And if I can build on what Demetre was saying, think about the Ebola outbreak in West Africa in 2014, and the cases that popped up in Nigeria. That led to all sorts of concern. Now you've got someone who has Ebola in Lagos, a city of twenty million people, and just not a city that necessarily has the sort of infrastructure in place that you're going to think, oh, we're going to be able to contain this. But they were able to repurpose existing programs. They were able to use measles control programs and other sorts of programs. And, using the word that we have all become way too familiar with over these past two and a half years, they pivoted, turned that into doing the surveillance and doing the contact tracing for Ebola, and were able to stop the spread, and being able to prevent that from spreading rampantly throughout one of the largest cities in the world. And I think that's the sort of thing, you know? If we have these sorts of structures in place, we can adapt them. Even if they are for one purpose, they can be adapted for other purposes. And so it's not that we need to recreat the wheel each time, it's that we need to figure—we need to make sure that we've got enough wheels out there, essentially. DASKALAKIS: And that goes for surveillance. Maintaining good surveillance systems for chronic things means that when an acute thing comes up, that good surveillance already exists there. So not only for an operation, but also for being able to understand what's happening with the threat. I like to call it keeping the system warm, if you think of sort of the stuff that's happening. So when you have to heat it up, you're not starting from—it's not a TV dinner you're taking out from frozen. It's thawed already. You can move quickly. NUZZO: It's really hard to build capacities in the midst of an emergency. So thank you for those thoughts. I am going to give others a turn to ask questions and turn it over to the question-and-answer session now. OPERATOR: Thank you. (Gives queuing instructions.) Our first question comes from Mark P. Lagon from Friends of the Global Fight against AIDS, Tuberculosis, and Malaria. LAGON: Hi, there. Thank you for this really thought-provoking forum. I come from a perspective working in the health field, but also background in human rights. I was an adjunct senior fellow at CFR, and president of Freedom House. I wonder, to take some of the points that Jennifer Nuzzo has been making and posing to you, to move to pandemic preparedness. If you have—we've seen that AIDS confronts one with very clear human rights and equity issues, particularly for stigmatized populations. You have a kind of a reprise with monkeypox. There was a lot of discussion about in terms of the impact of COVID and equity on vaccines. As the international community has moved to form a fund housed at the World Bank, how do you embed preparation for pandemics to have a human rights or social justice perspective? Activists really had to push hard to get two voting seats for civil society on the governing body of that fund. Thank you. NUZZO: Anyone want to take that on? (Laughs.) YOUDE: Sure. I'll offer a few thoughts. I think this is something—again, this is something to be thinking about at this early stage. As these sorts of systems are being designed, as they're being set up, keeping these sorts of elements important and at play. But I also think it's important to make sure that there are multiple channels for this communication to happen. That there's one thing to talk about formal board seats, and those are obviously important to have people at the table for these pandemic financing facilities through the World Bank and other sorts of organizations. But also make sure there are other opportunities, because new organizations may pop up. They may change. Depending on the particular circumstance or the particular outbreak that we're talking about, there may be other groups that are being mobilized and being affected by this. And so, there needs to be a certain level of nimbleness that needs to go into this. I think it's also something that puts a lot of—we need to put pressure on our leaders to really put their promises into action, to make sure that this isn't just something that we have as a tick box exercise. Oh, yes, equity is important, we need to address this. But actually, that there is this ongoing pressure and this sort of check of what are we actually doing here? Are we reaching out to these communities that are being affected? How can we better do this? And so I—again, there's an interesting moment right now that we can hopefully seize to make sure that this is something that really does get instantiated within these systems. And I hope we don't let that moment pass. I hope we don't decide to just we'll go back to existing systems. Because that's the other thing that goes along with this. It does challenge the status quo. It does challenge the sorts of standard operating procedures that we have in these organizations. And that can be challenging. That can be a difficult sort of conversation to have. And we have to be willing within our international organizations and other sorts of responses, we have to be willing to have those conversations. We have to be willing to challenge ourselves and to criticize ourselves, and to then make changes that are going to be effective. LAGON: Thank you. DASKALAKIS: I don't have almost anything to add to what Jeremy said. I think there really—again, the political will is important. And just we've all experienced that U-shaped curve of concern, right, where when things are very exciting everyone is very worried and engaged, and then when it fades away, resources fade away. And what that means is the infectious disease comes back. And so it's really—whether it's the same or a different infectious disease, sort of keeping that momentum and having it really come both from the political piece, from organization, but also from the side of advocates and activists is really critical to keep the—to keep the energy moving and the momentum moving. We have to make sure that we come to a better place. Every event, you learn more. And so I think that even if we take a quantum leap in what preparedness looks like, whatever the next event will challenge that level of preparedness and will require us to then—to really develop systems that are—that are updated based on the experience. So I think moving the needle anywhere, but moving it in a coordinated way because of that will and that strategy is the most we could hope for and the most we should expect. Or the least that we should expect, the minimum, of being able to move to a place where we have something that is better than how we found it, and potentially more resilient in terms of a—monkeypox is minor compared to COVID, after COVID. NUZZO: Yeah. I mean, I think the more we have these events the more we learn, though it does feel to me a little bit like the more we have these events, the more we learn the same things over and over again. (Laughs.) And particularly when we're talking about these inequities. And Jeremy pointed out about the stark inequities in terms of who's able to access vaccines in the globe. And that was clearly something that we saw throughout much of COVID-19, still see it today. We saw it during the 2009 H1N1 pandemic, in terms of who had vaccines and who didn't. So I guess the question—and I recognize that we have just about ten minutes left, and the CFR rule is we always end on time. So I'm going to—(laughs)—I'm going to be aggressive about that. But just on that point what do we need, I think, to put into place? We talked about how there's a pandemic fund now, which is important. But aside from money, and maybe it's just money, what else do we need to kind of create structures to address these inequities globally? Given, Jeremy, you also made the important point about—I've been struck by how hard it's been to contain monkeypox here in the U.S. But let's say we're successful, we're still going to have challenges as the virus continues to circulate. So we need to make progress globally. And we need to have systems in place such that every time these emergencies happen, we don't keep learning these same lessons over. So maybe just two or three minute each, your takeaways on what you would do to fix these problems if you were deemed in charge of the world. YOUDE: A little new world, just like that. Money is obviously important. The amount of money that we spend on development assistance for health has gone up dramatically since the early 1990s, but it still pales in comparison to the level of need. So there is just a basic resource need. The second is that we need to make sure that systems that we are building are not for specific diseases, but are things that can be flexible, things that can be adapted. We don't want to just say: Now we're going to set up all these monkeypox surveillance systems, when that may or may not be what is going to be the next big outbreak. So we need to have things that are going to be able to be flexible like that. Third, we need to have—we need to have a better sense of just our—I guess our international community's willingness to engage with global health. We have the international health regulations. So we do have an international treaty that's supposed to govern how states respond to infectious diseases and their outbreaks. But the willingness of states to abide by that varies quite dramatically. And so we need to have a big of a come-to-Jesus moment about what are we actually willing to do, when push comes to shove? And then last thing I'll say is that I do think we need to have a conversation around access to pharmaceuticals and vaccines and other sorts of medical interventions like that. Because we know that there are inequities, and we know that oftentimes the communities that have the least access are the communities that have the highest rates of incidence or are in the most need of these sorts of things. And our structures are not really well designed for getting people access. Even though there are things like COVAX, even though there are things like PEPFAR, and all these other sorts of programs, which have done tremendous work, they are still falling short. And so we need to—we need to have a better sense of what—how do we actually put these sorts of things into practice? How do we actually make sure that these scientific breakthroughs that are so invaluable are reaching all the people that need to be reached? DASKALAKIS: Ditto, I'll start off. So that makes my job a little bit easier, because I think what Jeremy said is really important. I'll say again, I think in my hierarchy the first and most important thing is consistent political will, because I think that that then drives a lot of what happens beyond that. So I think that that really jives really well with what Jeremy said, in terms of that sort of commitment. Money is very important, I think, but it is not the only thing that drives us into preparedness. So I think that having that commitment. I also would like to think about that investing the money in things that keep the system warm. So I'll go back to that sort of statement, or like thinking about investing in the diseases that we still haven't finished. We still are working—we've got HIV, we have hepatitis, malaria internationally that we're worried about. There are a lot of areas that we could invest to create systems that are infrastructures that keep it warm for operation for pandemic. I cannot say it loud enough that what Jeremy said about flexibility is right. You can't really build the infrastructure on chronic disease if it's not flexible to move to another acute event. So it needs to be something that is both creates and maintains the infrastructure, but also has the ability—everyone's favorite word today—to pivot into the emergency response zone. So very important. I think also workforce and data. I think that it is important to remember that we talk about giving patients trauma-informed care, but we need to give our workforce trauma-informed care. COVID has been hard. Monkeypox has been hard. Our next challenge will be hard. And sort of how can we support the workforce and then also continue to mentor it to be able to do the work? Data also is so important. A commitment to share data, and to have data that is accessible for decisions, even if it is imperfect. And then finally, the realization—and it goes back full circle, Jennifer, to your first question—about our—or, maybe second question—about the social determinants. There's only so much that public health can do. There is an all-of-society need to address the core drivers of so many of the inequities. We can't solve everything through public health. We can get closer to health equity, but ultimately the goal is that as you access is really to go into social justice, which is not just public health but really an all-of-society endeavor to try to improve the environment so that we don't have fertile ground for these pandemics to blossom and grow. NUZZO: Thank you. There's a question that just popped up in the Q&A box. And we just have a few minutes. It's about the privilege of good information and how we address misinformation and disinformation, which likely leads to fragmentation. I will just chime in, having done a lot of communication over the past two years, I think that this is not a problem that public health can solve. I actually think the drivers of this are much, much larger. And I think we need an all-of-government approach to this that includes the potential regulation of the platforms. But I'm curious if you all have any quick comments to add to that. DASKALAKIS: I mean, I just agree with you. (Laughs.) It's definitely much bigger. There are things we can do, like monitor social media and make sure that our messaging is one way. But ultimately this is an issue that's bigger, that requires not just the public health lens to address. YOUDE: And, at the same time, we also can recognize that those trusted outlets, those can be really important tools. So, churches in sub-Saharan Africa played a really crucial role in many parts of helping to decrease HIV stigma, helping to get access and information out there about testing, about protection, about these sorts of things. I mean, that can also be the flipside, though. If you got these trusted sources that are peddling this misinformation, then it becomes this much bigger issue that goes beyond what public health can do. So I guess it's—part of it is just figuring out where those allies exist, be they in government or outside of the government, and what sorts of connections they might have with populations. DASKALAKIS: And to your earlier point about building those connections prior to events, so those relationships exist and you're not trying to forge them in the midst of a crisis. NUZZO: Well, really, thank you both. I wish I could appoint you both in charge of the world, because if I was asked who should be in charge of the world you would both be on the top of my list. But I am very glad that you continue to do the work that you do and contribute in important ways. And have both been really guiding voices as we continue to experience these events. So thank you very much for that, and really thank you to our participants for attending and the thoughtful questions. FASKIANOS: I second that. Thank you all. And we appreciate your taking the time to do this. I hope you will all follow their work. For Dr. Daskalakis, you can follow him at @dr_demetre. Dr. Youde is at @jeremyyoude. And Dr. Nuzzo is at @jennifernuzzo. Pretty easy. So we also encourage you to follow CFR's Religion and Foreign Policy Program on Twitter at @CFR_religion and write to us at outreach@CFR.org with any suggestions or questions. We want to help support the work that you all are doing. And we hope you will join us for our next Religion and Foreign Policy Webinar on the Politics of Religion and Gender in West Africa, on Tuesday October 11 at 12:00 p.m. Eastern time. So thank you all again for being with us, and thank you for your public service. We appreciate it.

Yet another mass shooting has taken place in the United States and this time it was at an elementary school. Yet, the government continues to do nothing. In this special double episode, David Rothkopf and Kavita Patel talk with Laurie Garrett about the shooting in Texas as a public health crisis and then later are joined by Mary McCord of Georgetown University to talk about potential legal responses to mass shootings. What can public health tools reveal about the epidemic of mass shootings happening in the United States? How has the growth of conspiracy theories impacted these shootings and public health more broadly? What can we do to stop the violence? The answer to these vitally important questions in this thoughtful conversation. Don't miss it.Support this show http://supporter.acast.com/deepstateradio. See acast.com/privacy for privacy and opt-out information.

Yet another mass shooting has taken place in the United States and this time it was at an elementary school. Yet, the government continues to do nothing. In this special double episode, David Rothkopf and Kavita Patel talk with Laurie Garrett about the shooting in Texas as a public health crisis and then later are joined by Mary McCord of Georgetown University to talk about potential legal responses to mass shootings. What can public health tools reveal about the epidemic of mass shootings happening in the United States? How has the growth of conspiracy theories impacted these shootings and public health more broadly? What can we do to stop the violence? The answer to these vitally important questions in this thoughtful conversation. Don't miss it.Support this show http://supporter.acast.com/deepstateradio. See acast.com/privacy for privacy and opt-out information.

Are you better off than you were the last day Trump was in office? Clay says he doesn't think many people are. Biden gives speech on inflation, has no answers besides more spending, which will only make it worse. Buck, plays Rick Santelli's "prophetic" statement and agrees, "Prices aren't going back down, folks." We need to run out the clock on Biden in 2022, Clay says and then passionately reiterates. And then we ride the red wave in November. Golden State head coach Steve Kerr coaches playoff game in mask, tests positive anyway. Viral clip from pandemic expert Laurie Garrett in 2018: Masks scare people, but don't work. Dr. Fauci: cult leader of the lockdowners. Rand Paul: Dr. Fauci has normalized untruths. Clay asks: "Have you ever disliked anyone in the public sphere more than you dislike Fauci?" See omnystudio.com/listener for privacy information.

Are you better off than you were the last day Trump was in office? Clay says he doesn't think many people are. Biden gives speech on inflation, has no answers besides more spending, which will only make it worse. Buck, plays Rick Santelli's "prophetic" statement and agrees, "Prices aren't going back down, folks." We need to run out the clock on Biden in 2022, Clay says and then passionately reiterates. And then we ride the red wave in November. Golden State head coach Steve Kerr coaches playoff game in mask, tests positive anyway. Viral clip from pandemic expert Laurie Garrett in 2018: Masks scare people, but don't work. Dr. Fauci: cult leader of the lockdowners. Rand Paul: Dr. Fauci has normalized untruths. Clay asks: "Have you ever disliked anyone in the public sphere more than you dislike Fauci?" See omnystudio.com/listener for privacy information.

John Abramson served as a family physician for 22 years. And was voted “best doctor” numerous times. He is a Harvard Medical School faculty member, where he currently teaches health care policy. He transitioned to litigation as a consultant to the FBI and Department of Justice  and served in many trials against big pharmaceutical companies. Dr. Abramson has appeared on more than 65 national television shows and podcasts, including the Today Show, the Joe Rogan Experience, Dr. Oz Show, Lex Friedman and now LTR. His writing has been published in places like the New York Times, LA Times and he is the author of the national best-selling book Overdo$ed America.Recently he published his second book Sickening and we are so grateful to have him here today to talk about how lack of transparency in pharmaceutical trials is impacting the healthcare system and what you as a future leader need to know about it.Questions We Asked: How did you transition from a family physician to litigation and writing work? What inspired you to write your second book, Sickening? What are a few examples of pharmaceutical case trials that have impacted patients? How can doctors learn about how drugs are marketed and what the data shows? Should there be a governmental body that vets clinical trial data? How should physicians decide which drugs to support and give their patients?How do we incentives caring for the patient? What advice would you give your younger self? Book Suggestions? Quotes & Ideas: Peer reviewers only get to see the submitted data instead of the raw data. This allows for cherry picking of data to prove effectiveness and maximize profits, not improve health. Most medical journals profit from sending reprints to pharmaceutical companies which creates an incentive to make the pharmaceutical drugs look good. Milton Freedman's 3 roles of government, “It should provide for military defense of the nation. It should enforce contracts between individuals. It should protect citizens from crimes against themselves or their property.”US healthcare is alone in allowing commercialization permeate the healthcare system from drug advertisements to device sales and more The US healthy life expectancy has decreased from 38th in the world to now 68th in the world The system is designed to allow commercial interests to maximize drug companies profits instead of maximize the ability of physicians to deliver quality care Book Suggestions: Overdo$ed America and Sickening by Johnathon Abramson How Markets Fail by John CassadyPhishing for Phools by George AkerlofBetrayal of Trust by Laurie Garrett 

It has been two years since COVID-19 started hitting the headlines globally. As the new omicron variant is causing surging caseloads across America and around the world, it seems as though the end of this moment is very far away. What mistakes have we made? What should the Biden administration be doing next? How does the pandemic connect to the fight to protect democracy? What does the Supreme Court decision on the vaccine mandate mean for the fight against the virus? To answer these and other pressing questions, DSR Host David Rothkopf spoke with Kavita Patel of the Brookings Institution and Pulitzer Prize winning journalist Laurie Garrett. Don't miss this timely conversation.Support this show http://supporter.acast.com/deepstateradio. See acast.com/privacy for privacy and opt-out information.

Often referred to as the "Pandemic Prophet," noted science journalist Laurie Garrett chats with us about the COVID 19 pandemic, the state of global health, whether or not it really is safe to wear masks, politics, and so much more. Be in the know in 30ish minutes. Laurie Garrett wrote her first bestselling book, THE COMING PLAGUE: Newly Emerging Diseases in a World Out of Balance, while splitting her time between the Harvard School of Public Health and the New York newspaper, Newsday. In the 1992-93 academic years Garrett was a Fellow at Harvard, where she worked closely with the emerging diseases group, a collection of faculty concerned about the surge in epidemics of previously unknown or rare viruses and bacteria. The book was published in hardcopy by Farrar, Straus, and Giroux in 1994, and spent 19 weeks on the New York Times bestseller list. (Source: lauriegarrett.com) Learn more about your ad choices. Visit megaphone.fm/adchoices

Andy gets back to basics with Pulitzer Prize-winning science journalist Laurie Garrett. They get into how and why viruses mutate, why the variants don't seem to be causing too much trouble for the mRNA vaccines, and how our actions are, as Laurie puts it, "aiding and abetting" COVID. Plus, her big takeaways for how a little empathy at home and in our systemic approach can change the trajectory of the pandemic.   Keep up with Andy on Twitter @ASlavitt and Instagram @andyslavitt.    Follow Laurie @Laurie_Garrett on Twitter.   Joining Lemonada Premium is a great way to support our show and get bonus content. Subscribe today at bit.ly/lemonadapremium.    Support the show by checking out our sponsors!   Click this link for a list of current sponsors and discount codes for this show and all Lemonada shows: https://lemonadamedia.com/sponsors/  Throughout the pandemic, CVS Health has been there, bringing quality, affordable health care closer to home—so it's never out of reach for anyone. 

Learn more at cvshealth.com.   Check out these resources from today's episode:    Learn more about Laurie: https://www.lauriegarrett.com/ Read more on the hunt for a “universal” COVID-19 vaccine: https://fortune.com/2021/08/18/universal-covid-vaccine-delta-variant-gritstone-cepi/ Check out the status of coronavirus vaccinations around the world: https://www.nytimes.com/interactive/2021/world/covid-vaccinations-tracker.html Learn more about Gavi, the Vaccine Alliance: https://www.gavi.org/ Find a COVID-19 vaccine site near you: https://www.vaccines.gov/  Order Andy's book, Preventable: The Inside Story of How Leadership Failures, Politics, and Selfishness Doomed the U.S. Coronavirus Response: https://us.macmillan.com/books/9781250770165    Stay up to date with us on Twitter, Facebook, and Instagram at @LemonadaMedia.    For additional resources, information, and a transcript of the episode, visit lemonadamedia.com/show/inthebubble. See omnystudio.com/listener for privacy information.

Pfizer announced Monday that its coronavirus vaccine demonstrated more than 90% effectiveness and no serious bad reactions in trial results — an outcome that should enable the company to obtain an emergency authorization soon. Between the vaccine and the unveiling, also on Monday, of a Biden-led coronavirus task force, it seemed like the rare pandemic-era day in which the good news could compete with the tragic. But Pulitzer Prize–winning science writer Laurie Garrett wrote this week in Foreign Policy that even if this vaccine works as advertised, there are still plenty of reasons to worry about much good it can do. In this podcast extra, Garrett tells Brooke about what she views as caveats to the potential breakthrough.  CORRECTION: This podcast contains an error concerning the timing of testing after the second dose of Pfizer's coronavirus vaccine candidate. According to a protocol released by Pfizer, Phase 3 study participants were tested for coronavirus "at least 7 days after receipt of the second dose," [emphasis added]. In this interview, Garrett says, "7 days after [the second dose], [participants] got a COVID test. The results presented are what was found at that seven-day point." Rather, the results announced by Pfizer earlier this month were based on testing conducted at least one week after the second dose.  We reached out to Garrett for additional comment, and she added this: "All [Pfizer's] protocol required was a single test at the 7 day point. Eventually, Pfizer has extended that to 14 days. Since we don't have any breakdown on numbers in the only published info — press release — we don't know what % of the vax recipients were tested at 7 days, 8 days, 12 days…..no idea. So all we CAN say is that they all got a minimum of response time before testing. It's a glass half full, half empty issue." On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing onthemedia@wnyc.org.

In this week's America: Changed Forever, are we truly 'changed forever?' Anchor Gill Gross speaks with Pulitzer Prize winning health author Laurie Garrett about a coronavirus vaccine and if it will truly get us back to "normal." And a look coronavirus protections against evictions and if they are helping tenants stay in their homes.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Pulitzer-winning Laurie Garrett, author of The Coming Plague: Newly Emerging Diseases in a World Out of Balance, talks about the dangers of politicians offering coronavirus misinformation.

CBS Audio presents a special program focusing on the impact that the coronavirus has had on American society and what comes next in our fight against the virus. Host Gil Gross interviews legendary sportscaster James Brown, Pulitzer Prize-winning journalist Laurie Garrett and biotech executive Jim Greenwood and more to discuss potential solutions to the current situation.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Empty grocery store shelves, Purell selling at $100 a bottle, and handwashing that would make any mother proud. Uncertainty about coronavirus dominates daily lives today all around the globe. But along with the many unknowns come solid reasons for hope, if the right steps are taken immediately. Acclaimed health expert Laurie Garrett argues that the window to mitigate the pandemic's effect is closing, but there is still much governments and individuals can do to curb the impact. Subscribe to the GZERO World with Ian Bremmer Podcast on Apple Podcasts, Spotify, or your preferred podcast platform, to receive new episodes as soon as they're published.

0:08 – Monday's with Mitch: The Trump Administration announced its reached a peace deal with the Taliban and an agreement to pull troops out of Afghanistan; 2020 Democratic field is shrinking: Mayor Pete and Tom Steyer drop out; plus more on Super Tuesday. 0:34 – Primary Election 2020 Debate: Oakland's Measure Q, a parcel tax of $148 per parcel to raise approximately $21 million per year for parks maintenance and homeless services, and provides a low-income senior exemption. The ballot question is as follows: “Shall a measure to provide: homelessness support services and programs to help homeless individuals move into shelters and housing; trash removal from parks and creeks; safe, well-maintained parks and trails; clean, accessible park restrooms; improved water quality; and park facilities repairs, by enacting an annual $148 parcel tax for single-family parcels, and other parcels as specified, for 20 years, raising approximately $21,000,000 annually with exemptions for low-income seniors, be adopted? For: Brooke Levin, Yes on Q campaign Against: Marcus Crawley, No on Q campaign Debate: Oakland's Measure Q 0:51 – KPFA News: House Speaker Nancy Pelosi has a primary election in her San Francisco congressional district on Super Tuesday, and several challengers are vying to become the runner-up she'll face in November. KPFA's Ariel Boone has the story. 1:08 – COVID-19 and a proper public health response Laurie Garrett (@Laurie_Garrett) is a former senior fellow for global health at the Council on Foreign Relations and a Pulitzer Prize-winning science writer. She is the author of several books, including Ebola: Story of an Outbreak, The Coming Plague: Newly Emerging Diseases in a World Out of Balance and Betrayal of Trust: The Collapse of Global Public Health. Laurie Garrett on COVID-19 1:34 – KPFA News: Fresno County prosecutor Andrew Janz gained national attention in 2018 when came close to defeating incumbent Republican Devin Nunes in California's heavily Republican 22nd Congressional District.  Now, he's campaigning to become the first Democrat in decades to become the mayor of Fresno.  Janz is in a tight race with former Fresno police chief Jerry Dyer. Fresno, with its population of over half a million residents, it is the fifth largest city in California.  Vic Bedoian reports from Fresno. 1:30 – Election 2020: South Carolina primary results Kevin Alexander Gray (@KevinAGray) is a longtime South Carolina political organizer and analyst who has worked on many political campaigns. His books include Waiting for Lightning to Strike: The Fundamentals of Black Politics. He is co-editor of the book Killing Trayvons: An Anthology of American Violence. 1:47 – How the Democratic campaign organizing is looking on the ground Akela Lacy (@akela_lacy) is a political reporter with the Intercept, covering the Democratic Presidential race. The post “We've got to start testing widely” Laurie Garrett on the high risk profile and public health response for the coronavirus; Plus: We host a debate on Oakland's Measure Q parcel tax appeared first on KPFA.

As coronavirus spreads, the Center for Disease Control is warning Americans to take urgent precautions. Meanwhile, the White House says tune out and calm down. On this week's On the Media, what to expect as COVID-19 threatens to make its way through a ruptured body politic. Plus, amid so much focus on electability, a look at the millions of voters who swing from voting “blue” to simply not voting at all. 1. Journalist [@Laurie_Garrett] on the nature of contagions and how a nation of so-called “epidemic voyeurs” is reacting to a possible pandemic on American soil. Listen. 2. Farhad Manjoo [@fmanjoo], New York Times opinion columnist, on making prediction in an unpredictable world. Listen. 3. Ibram X. Kendi [@DrIbram], executive director of the Antiracist Research and Policy Center at American University and author of How to be an Antiracist, on the "other swing voter." Listen. Further reading: "The Wuhan Virus: How To Stay Safe," by Laurie Garrett, published by Foreign Policy on January 25, 2020. Garrett also recommends reading coronavirus coverage and commentary from STAT's Helen Branswell, Science Mag's Jon Cohen and Kai Kupferschmidt, and John Hopkins's Tom Inglesby.  Music: John Zorn - Berotim Cling Mansell & Kronos Quartet - Full Tense Nino Rota/Enrico Peranunzi & Charlie Haden - Fellini's Waltz Martyn Axe - German Lullaby Nino Rota - Il Casanova de Frederico Fellini David Bowie/Meridian String Quartet - Heroes   On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing onthemedia@wnyc.org.

Only on the "CBS This Morning" podcast, CBS News contributor Dr. Tara Narula explores the public health and global policy implications of the coronoavirus epidemic with global health expert Laurie Garrett and expert on Chinese domestic and foreign policy, Elizabeth Economy. Garrett, a Pulitzer Prize-winning science writer, explains how the outbreak compares to other crises like the SARS outbreak in 2003. And Economy discusses what coronoavirus tells us about China, Chinese politics and President Xi Jinping.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

In a recent, very important article published in Foreign Policy, my guest Laurie Garrett writes about how the World Bank was holding back funds to tackle the Ebola outbreak in the Democratic Republic of the Congo. An issue not very well known until her article. To look at this situation and more is Laurie Garrett. Laurie is a former fellow for Global Health at the Council on Foreign Relations and a Pulitzer Prize winning science writer and the author of a number of really good books.

HOW TO DISCOVER THE SECRETS IN LIFE The best things in life are born from coincidence. I am a firm believer in this. A year ago I was flying back from California. I started talking to the guy sitting next to me. Turns out he had  worked in almost every branch of government related to intelligence and diplomacy. Now he runs his own private intelligence company. He has information about every government in the world. He is paid a lot of money to reveal and analyze that information. But when we were on the plane, for basically four or five hours I asked him everything I could and got the most incredible detail about the state of affairs in the world. I'm almost afraid to reveal what we spoke about on the plane. Everything from "how to catch a liar" to "What is the Nigerian government specifically doing about oil prices" to "Will Trump win?" (and his answer turned out to be stunningly accurate). Then...a lost touch with him. He  was just a guy I sat next to on the plane for a few hours. We got off and went to live our separate lives. Until now. His new book is out: "Warnings" written with uber-diplomat Richard Clarke. What is he warning about? Everything. Where are the hidden potential catastrophes around the world. And how can we live with them. And how can we avoid them. And how can we figure out the warnings after these? He answers, he analyzes, he proves, and he does it from his 30 years of experience uncovering these things for the US government and now, through his company, for other governments and large institutions that can afford him.  The key is: "that  can afford him". Because now he comes on the podcast and just like the coincidence of meeting  him a year ago, he answers all of my questions again about his book. About the "Warnings". I love  when coincidence intersects real life. I saw his book, remembered him from our interaction, and we had the best time on the podcast. Read the book, listen to the podcast, and don't ignore the coincidences in your life. (But he is.) R.P. Eddy is the CEO or Ergo, one of the greatest super intelligent firms in the world. Governments hire him and his firm to spy on other governments. "Hopefully, I wasn't too indiscreet," he said, referring to the time on his plane.   I told him not to worry. "If you're not arrested by the end of this podcast, then you're okay." In his book, "Warnings: Finding Cassandras to Stop Catastrophes," R.P. covers all the major world catastrophes that could've been predicted and prevented: 9/11, Madoff, Fukushima, the financial crisis, AIDS, climate change. If we can learn to predict these, or at least learn how to figure out  how the correct experts are, then a lot of pain can be avoided. Experts warned us. But no one listened to them. R.P. calls these people "Cassandras." The name comes from greek mythology. Apollo (a god) wanted to sleep with Cassandra. She refused. So Apollo cursed her. "She could foretell any future disaster. She could see it in vivid color," R.P said. But the curse was that no one believed her. So she burned to death in a terrible attack. (An attack she knew was coming...) These people exist in real life. And R.P. wants us to notice them. So R.P, and his coauthor, Richard Clarke, started "The Annual Cassandra Award." They're giving away cash prizes (up to $10,000) to motivate people to find and nominate a true "Cassandras." This is the formula for spotting a "Cassandra..." How to detect a truth-teller (listen at [55:25]) The "Cassandras" featured in R.P's book are experts in their field. They have been for years. He told me about Laurie Garrett, the head of global health for the Council of Foreign Relations. She's the first person to ever win the Polk, the Pulitzer and the Peabody. "She foresaw the rise of HIV/AIDS when she was a radio reporter in San Francisco," R.P. said. "She saw these men dying of a disease called 'gay related immune deficiency,'...

If you want to sleep tonight, skip this episode of StarTalk All-Stars. Bill Nye, Chuck Nice and virus expert Laurie Garrett examine how we're fighting Zika, Dengue, West Nile, HIV and other viruses – and why the battle may not be going our way.